1. Home
  2. >News
  3. >Illumina And Helix Collaborate To Assess Prevalence Of New Sars Cov 2 Uk Variant B 1 1 7 In The Us And Develop National Surveillance Infrastructure
Skip to main content
News

Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US and Develop National Surveillance Infrastructure

January 15, 2021Public Health

Ready to see the whole picture?

Connect with our team to discover how Helix can transform your approach to genomic medicine.

Connect with us
Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US and Develop National Surveillance Infrastructure | Helix